Adherex Technologies, Inc., a development stage biopharmaceutical company, engages in the discovery and development of cancer therapeutics. The company has various products in the clinical stage of development, such as ADH-1, eniluracil, and sodium thiosulfate (STS). Its ADH-1 product targets N-cadherin, a protein present on certain tumor cells and established blood vessels that feed solid tumors. In addition, Adherex offers Eniluracil, an oral dihydropyrimidine dehydrogenase inhibitor; and STS, a drug that protects against disabling hearing loss associated with platinum-based anticancer agents. It has a development and licensing agreement with GlaxoSmithKline. The company was founded in 1996 and is based in Durham, North Carolina.